Evaluation of kidney and liver subacute toxicity induced by Bezalip-Pravastatin-Lopid antihyperlipidaemic compounds in rats

Renal and hepatic subacute toxicity induced by the antihyperlipidaemic drug s: Bezalip - Pravastatin and Lopid was investigated in rats using serum bio chemical parameters. Toxicological evaluation was performed in serum sample s following the administration of the therapeutic dose regimens of the comp ounds that were previously shown to be effective in inhibition of 3-hydroxy -methylglutaryl coenzyme A (HMG CoA) reductase, the enzyme controlling the rate-limiting step in the synthesis of cholesterol, and acyl -CoA cholester ol acyl transferase (ACAT) which converts intracellular free cholesterol to cholesterol ester. Renal and hepatic subacute toxicity was evaluated by me asuring enzyme activity or concentrations of: alanine aminotransferace, alk aline phosphatase, asparate aminotransferase, gamma-glutamyltransferase, gl ucose, potassium, sodium, blood urea nitrogen, uric acid and creatinine. Th e use of the above serum biochemical parameters indicated that the overall toxicity impact of antihyperlipidaemic drugs was Bezalip = Pravastatin < Lo pid. We have found that the Pravastatin -in contrast to the above antihyperlipid aemic drugs- only transiently affects the biochemical parameters associated with toxicity, but, it affects some of the biochemical parameters associat ed with hepatic and renal toxicity, up to a significantly lower extent than the antihyperlipidaemic drugs.